(Q37872269)

24 August 2017

1 reference

title

Novel molecular targeted therapies for refractory thyroid cancer (English)

1 reference

24 August 2017

5

Ezra E W Cohen

1 reference

24 August 2017

Cesar A Perez

1

1 reference

24 August 2017

Edgardo S Santos

series ordinal

2

1 reference

24 August 2017

Belisario A Arango

series ordinal

3

1 reference

24 August 2017

Luis E Raez

series ordinal

4

1 reference

24 August 2017

publication date

4 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

34

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

736-745

1 reference

Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor

24 August 2017

cites work

1 reference

21 January 2018

Cancer statistics, 2009

1 reference

7 January 2021

Increasing incidence of thyroid cancer in the United States, 1973-2002

1 reference

7 January 2021

Survival and death causes in differentiated thyroid carcinoma.

1 reference

7 January 2021

Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.

1 reference

7 January 2021

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

1 reference

7 January 2021

BRAF mutation in thyroid cancer

1 reference

7 January 2021

Where do we stand with targeted therapy of refractory thyroid cancer?--Utility of RECIST criteria

1 reference

7 January 2021

High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma

1 reference

7 January 2021

Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.

1 reference

7 January 2021

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

1 reference

7 January 2021

BRAF is a therapeutic target in aggressive thyroid carcinoma.

1 reference

7 January 2021

Phase II trial of sorafenib in metastatic thyroid cancer

1 reference

7 January 2021

Phase II trial of sorafenib in advanced thyroid cancer

1 reference

7 January 2021

Vascular endothelial growth factor: basic science and clinical progress

1 reference

7 January 2021

Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene

1 reference

7 January 2021

Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features

1 reference

7 January 2021

Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma

1 reference

7 January 2021

Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer

1 reference

7 January 2021

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

1 reference

7 January 2021

Motesanib diphosphate in progressive differentiated thyroid cancer.

1 reference

7 January 2021

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

1 reference

7 January 2021

Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis

1 reference

7 January 2021

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer

1 reference

7 January 2021

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer

1 reference

7 January 2021

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

1 reference

7 January 2021

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

1 reference

7 January 2021

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

1 reference

7 January 2021

MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma

1 reference

7 January 2021

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

7 January 2021

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

1 reference

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

7 January 2021

Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group

1 reference

7 January 2021

Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas

1 reference

7 January 2021

Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies

1 reference

7 January 2021

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

7 January 2021

RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.

1 reference

7 January 2021

Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines

1 reference

7 January 2021

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.

1 reference

7 January 2021

A phase II study of gefitinib in patients with advanced thyroid cancer.

1 reference

7 January 2021

Alteration of nucleosome structure as a mechanism of transcriptional regulation

1 reference

7 January 2021

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

7 January 2021

Histone deacetylases, transcriptional control, and cancer

1 reference

7 January 2021

Histone deacetylases and cancer: causes and therapies

1 reference

7 January 2021

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

7 January 2021

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

1 reference

7 January 2021

Novel histone deacetylase inhibitors in the treatment of thyroid cancer

1 reference

7 January 2021

Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo

1 reference

7 January 2021

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

7 January 2021

Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma

1 reference

7 January 2021

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

1 reference

7 January 2021

Epigenetic targets in hematopoietic malignancies

1 reference

7 January 2021

Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF7.

1 reference

7 January 2021

Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways

1 reference

7 January 2021

Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells

1 reference

7 January 2021

Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells

1 reference

7 January 2021

Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells

1 reference

7 January 2021

Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells

1 reference

7 January 2021

Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells

1 reference

7 January 2021

Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers

1 reference

7 January 2021

From the cradle to the grave: molecular chaperones that may choose between folding and degradation

1 reference

7 January 2021

Hsp90: a specialized but essential protein-folding tool

1 reference

7 January 2021

Requirement for a hsp90 chaperone-dependent MEK1/2-ERK pathway for B cell antigen receptor-induced cyclin D2 expression in mature B lymphocytes

1 reference

7 January 2021

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.

1 reference

7 January 2021

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

1 reference

7 January 2021

A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.

1 reference

7 January 2021

A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies

1 reference

7 January 2021

Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells

1 reference

7 January 2021

Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid.

1 reference

7 January 2021

17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels

1 reference

7 January 2021

Tyrosine kinases as targets for cancer therapy

1 reference

7 January 2021

The proteasome: a suitable antineoplastic target

1 reference

7 January 2021

Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma

1 reference

7 January 2021

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

7 January 2021

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

1 reference

7 January 2021

Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro

1 reference

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

7 January 2021

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

1 reference

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

7 January 2021

Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors

1 reference

7 January 2021

Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations

1 reference

7 January 2021

A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma

1 reference

7 January 2021

Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HED.21755

1 reference

24 August 2017

1 reference